Over the next decade, nanotechnology has the potential to influence virtually every aspect of our lives, including our energy, food, water, buildings, and medicines. According to a recently published report by BCC Research, the market value of the worldwide nanomedicine industry alone is estimated to grow at a CAGR of 12.5% to reach $130.9 billion by the fiscal year 2016. However, in order to realize this broad potential robust, cost-effective, regulatory-friendly manufacturing technologies will be required. Through its novel nanoparticle technology platform and expansive intellectual property, Liquidia is poised to be a leader in the development of nanotechnology-based healthcare products and a catalyst for the growth anticipated across this industry. Learn more >
ANNOUNCEMENTS
May 21, 2013 Liquidia announces Extension of Collaboration with PATH to Develop Next Generation Pneumococcal VaccineDetails
May 6, 2013 Liquidia Technologies Presents Preclinical Ophthalmology Data at 2013 ARVO Annual MeetingDetails
May 2, 2013 Liquidia Announces Plan to Form Ophthalmology Company to Support Product Development StrategyDetails
April 23, 2013 Liquidia CEO Neal Fowler panelist at BIO International in ChicagoDetails
March 4, 2013 New Ophthalmology page added to Liquidia websiteDetails
RECENT NEWS
May 3, 2013 Reuters: Big Drugmakers Think Small with Nanomedicine DealsDetails
May 2, 2013 TBJ: Liquidia CEO to Run Spin-off Company, Consider adding JobsDetails
April 18, 2013 Liquidia and GSK award ViE Award for Best Vaccine Licensing Deal at World Vaccines in Washington DCDetails
January 4, 2013 TBJ: Neal Fowler among Triangle Business Journal's Top 10 People to Watch in 2013
Details
August 28, 2012 Liquidia Technologies Appoints Dr. Benjamin Yerxa as Chief Scientific Officer
Details
